Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Welcome to OncoDaily’s special section “Oncologist Near Me”, where we introduce prominent oncologists from around the world.

Here, you can get to know the leading cancer specialists in your area, including both personal and professional details that you won’t find in their research articles.

Interested solely in research? We’ve got that covered too! Discover top research articles by the author, learn about their academic achievements, awards, and honors, watch their interviews, and memorize some quotes for much-needed inspiration!

We’ve curated the internet to find the most important information about them. If you have more information, please don’t hesitate to contact us at [email protected].

Fabrice André, MD, PhD

Fabrice André is a distinguished medical oncologist specializing in breast cancer. He currently serves as the Director of Research at Gustave Roussy in Villejuif, France, and is a Professor of Medicine at the University of Paris-Saclay. In addition to his academic and clinical achievements, Dr. André is the President of the European Society for Medical Oncology (ESMO), a role that underscores his leadership in advancing global cancer care.

Early Life and Career

Fabrice André, born on May 10, 1972, pursued his secondary education in Villard-de-Lans and higher studies in Grenoble. He earned his medical degree in oncology from the University of Grenoble in 2002 and completed a PhD in Biotechnology at the University of Paris in 2005, with a thesis titled “Cancer Immunotherapy.” Following this, he served as a Visiting Assistant Professor at the MD Anderson Cancer Center in Texas in 2006.

Dr. André completed his residency in Medical Oncology at Gustave Roussy, where he became a University Professor-Hospital Practitioner in the Department of Medical Oncology in 2012.

From 2010 to 2016, Dr. André directed the Inserm 981/Gustave Roussy/Université Paris-XI joint research unit, focusing on predictive biomarkers and novel molecular strategies in anticancer therapy. In 2010, he created his research lab at Gustave Roussy. Since 2020, he has held the position of Research Director at Gustave Roussy, continuing his groundbreaking work in oncology.

Career at ESMO

Professor André is the current President of the European Society for Medical Oncology (ESMO) for the 2025-2026 term. He was selected as President-Elect of the European Society for Medical Oncology (ESMO) on June 27, 2022. for the term 2025-2026.

He served on the Annals of Oncology Editorial Board from 2010 to 2013, became an Associate Editor in 2014, and held the position of Editor-in-Chief from 2017 to 2023.

He was the first chair of the ESMO Young Oncologist Committee, and he has been involved with the ESMO Breast Cancer Faculty as its coordinator from 2012 to 2014. He has been a member since 2015. Additionally, Professor André was a member of the ESMO Cancer Research Faculty from 2012 to 2014, chaired the ESMO Translational Research and Precision Medicine Working Group until the end of 2019, and has been a member since 2020. He is also a part of the ESMO Council and served as the Scientific Co-Chair of both the ESMO 2022 Congress and the MAP Congress.

ESMO has played a pivotal role in shaping his career, providing him with opportunities for leadership and collaboration that have significantly contributed to his expertise and recognition in the field of oncology.

Research

Professor André’s research centers on biomarkers and personalized therapies, emphasizing biomarker discovery, the development of targeted agents, and the integration of personalized medicine. His team of 80 professionals specializes in basic sciences, bioinformatics, biotechnology, and clinical research. He also leads Phase I-III clinical trials investigating targeted therapies for breast cancer, as well as large-scale national studies on incorporating high-throughput technologies into healthcare systems.

With over 300 peer-reviewed publications, including leading contributions in Nature, The New England Journal of Medicine, The Lancet, and Nature Medicine, Professor André is a prominent figure in his field. He serves as chairman of the biomarker group at UNICANCER (the French cooperative group) and has been part of scientific committees for numerous international conferences, such as SABCS, AACR, ECCO, ESMO, and IMPAKT.

In an interview marking the 35th Anniversary of Annals of Oncology, Professor Fabrice André emphasized that the primary goal of research should not be publication but advancing the field and improving patient outcomes. He stated, “My main advice is that publication should not be the ultimate goal of research. The true aim is to advance the field and help patients, and this is the spark that produces the most impactful, high-quality research. Publishing is merely a tool for sharing knowledge and spreading your findings to a broader audience.”

Aachivments and Awards

His pioneering contributions to biomarker discovery, personalized therapies, and the development of targeted agents have earned him numerous prestigious awards throughout his career, here are some of the awards:

Research

Professor André’s research centers on biomarkers and personalized therapies, emphasizing biomarker discovery, the development of targeted agents, and the integration of personalized medicine. His team of 80 professionals specializes in basic sciences, bioinformatics, biotechnology, and clinical research. He also leads Phase I-III clinical trials investigating targeted therapies for breast cancer and large-scale national studies on incorporating high-throughput technologies into healthcare systems.

With over 300 peer-reviewed publications, including leading contributions in Nature, The New England Journal of Medicine, The Lancet, and Nature Medicine, Professor André is a prominent figure in his field. He serves as chairman of the biomarker group at UNICANCER (the French cooperative group) and has served on scientific committees for numerous international conferences, such as SABCS, AACR, ECCO, ESMO, and IMPAKT.

In an interview marking the 35th Anniversary of Annals of Oncology, Professor Fabrice André emphasized that the primary goal of research should not be publication but advancing the field and improving patient outcomes. He stated, “My main advice is that publication should not be the ultimate goal of research. The true aim is to advance the field and help patients, and this is the spark that produces the most impactful, high-quality research. Publishing is merely a tool for sharing knowledge and spreading your findings to a broader audience.”

Beyond The White Coat

Dr. André has a lifelong love for skiing, a hobby he developed as a young boy. His talent and determination led him to earn the 10th-highest rank in downhill ski racing in France during his youth, showcasing the same drive and focus that he brings to his professional and personal life.

In 2024, Fabrice André participated in the Marathon of the Harmonie Mutuelle Semi de Paris, one of the most prestigious races in the world. His goal was to support cancer research conducted at Gustave Roussy and to offer new hope to the thousands of patients treated there each year.

Photo credit to Fabrice André/LinkedIn. 

Interviews with Fabrice André

Annals of Oncology 35th Anniversary – Interview with Prof. Fabrice André

MAP conference: an interview with Fabrice André

Behind the Breakthroughs: The Future of Personalized Medicine with Fabrice André – BCRF, 2022

Fabrice André: “We need real political will to move from mass medicine to precision medicine” – ROSE-UP

France 2030 – Interview with Fabrice André

Top 10 papers by Fabrice André*

1. André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Pápai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D; SOLAR-1 Study Group. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019 May 16;380(20):1929-1940. doi: 10.1056/NEJMoa1813904. PMID: 31091374.
2. AACR Project GENIE Consortium. AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov. 2017 Aug;7(8):818-831. doi: 10.1158/2159-8290.CD-17-0151. Epub 2017 Jun 1. PMID: 28572459; PMCID: PMC5611790.
3. Andre F, Schartz NE, Movassagh M, Flament C, Pautier P, Morice P, Pomel C, Lhomme C, Escudier B, Le Chevalier T, Tursz T, Amigorena S, Raposo G, Angevin E, Zitvogel L. Malignant effusions and immunogenic tumor-derived exosomes. Lancet. 2002 Jul 27;360(9329):295-305. doi: 10.1016/S0140-6736(02)09552-1. PMID: 12147373.
4. Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M, Meric-Bernstam F, Wagle N, Stenzinger A, Bonastre J, Bayle A, Michiels S, Bièche I, Rouleau E, Jezdic S, Douillard JY, Reis-Filho JS, Dienstmann R, André F. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020 Nov;31(11):1491-1505. doi: 10.1016/j.annonc.2020.07.014. Epub 2020 Aug 24. PMID: 32853681.
5. Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, Soria JC, Dien AT, Adnani Y, Kamal M, Garnier S, Meurice G, Jimenez M, Dogan S, Verret B, Chaffanet M, Bachelot T, Campone M, Lefeuvre C, Bonnefoi H, Dalenc F, Jacquet A, De Filippo MR, Babbar N, Birnbaum D, Filleron T, Le Tourneau C, André F. Genomic characterization of metastatic breast cancers. Nature. 2019 May;569(7757):560-564. doi: 10.1038/s41586-019-1056-z. Epub 2019 May 22. Erratum in: Nature. 2019 Aug;572(7767):E7. doi: 10.1038/s41586-019-1380-3. PMID: 31118521.
6. Andre F, Grunenwald D, Pignon JP, Dujon A, Pujol JL, Brichon PY, Brouchet L, Quoix E, Westeel V, Le Chevalier T. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol. 2000 Aug;18(16):2981-9. doi: 10.1200/JCO.2000.18.16.2981. PMID: 10944131.
7. André F, Chaput N, Schartz NE, Flament C, Aubert N, Bernard J, Lemonnier F, Raposo G, Escudier B, Hsu DH, Tursz T, Amigorena S, Angevin E, Zitvogel L. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol. 2004 Feb 15;172(4):2126-36. doi: 10.4049/jimmunol.172.4.2126. PMID: 14764678.
8. André F, O’Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C, Yap YS, Papai Z, Lang I, Armstrong A, Lerzo G, White M, Shen K, Litton J, Chen D, Zhang Y, Ali S, Taran T, Gianni L. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014 May;15(6):580-91. doi: 10.1016/S1470-2045(14)70138-X. Epub 2014 Apr 14. PMID: 24742739.
9. Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delaloge S, Curigliano G, Andre F. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014 Mar;25(3):611-618. doi: 10.1093/annonc/mdt556. Epub 2014 Jan 8. Erratum in: Ann Oncol. 2015 Jul;26(7):1518. doi: 10.1093/annonc/mdv241. PMID: 24401929; PMCID: PMC3933248.
10. Andre F, Slimane K, Bachelot T, Dunant A, Namer M, Barrelier A, Kabbaj O, Spano JP, Marsiglia H, Rouzier R, Delaloge S, Spielmann M. Breast cancer with synchronous metastases: trends in survival during 14 years. J Clin Oncol. 2004 Aug 15;22(16):3302-8. doi: 10.1200/JCO.2004.08.095. PMID: 15310773.

*Most cited papers, where Pashtoon Kasi is the first or last author according to Google Scholar

Quotes from Fabrice André

• Because we are in a field where people are usually modest, they don’t step back to realize that anything they do could have a huge worldwide impact. This is something that people, especially when they are young, need to realize.
• Publication should not be the ultimate goal of research. The true aim is to advance the field and help patients, and this is the spark that produces the most impactful, high-quality research. Publishing is merely a tool for sharing knowledge and spreading your findings to a broader audience.

How to contact him?

Email: [email protected]
Location: 114, rue Édouard-Vaillant, 94805 Villejuif Cedex – France

References

1. Fabrice André, (January 2025) – European Society of Medical Oncology
2. Professor Fabrice André – Gustave Roussy
3. Honoring Excellence in Breast Cancer Research and Advocacy: Meet the 2024 Susan G. Komen Award Recipients, (December 11, 2024) – Susan G. Komen Foundation
4. Fabrice André – Inserm
5. Annals of Oncology 35th Anniversary – Interview with Prof. Fabrice André – European Society of Medical Oncology
6. This year’s GIANTS OF CANCER CARE (ASCO) award goes to Prof. Fabrice André, a member of our Scientific Board – ISREC.
7. Expert Point of View: Fabrice André, MD, PhD, (November 2022) – The ASCO Post
8. Top 100 Xfluencers in Breast Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024 – OncoDaily
9. Fabrice André has been elected as the President of the ESMO for the term 2025-2026 – OncoDaily

See also:

• Oncologist Near Me – Lillian Siu: Curiosity-Driven Cancer Innovator
• Oncologist Near Me: Pashtoon Kasi – Pioneering Cancer Specialist
• Oncologist Near Me – Eric Small: Prominent Prostate Cancer Specialist
• Oncologist Near Me – Julie R. Gralow: A Visionary Leader in Global Cancer Care